General discussion, page-11844

To add on to this - we've been talking a lot about the macro trends affecting us in the form of fear/sentiment driving a lot of share prices down.

But a more positive wider trend affecting us is Big Pharma's appetite and ability to make big deals in 2022, especially someone like Pfizer who had about $50b USD revenue from Covid alone and now has a tonne of cash. Pfizer also has demonstrated an interest in our space with their recent $6.7b USD acquisition of Arena Pharmaceuticals.

"Eighteen large-cap U.S. and European biopharmas will have more than $500 billion in cash on hand by the end of 2022, SVB Leerink analyst Geoffrey Porges and his team wrote in a Wednesday note. The companies could use the money to strike deals, pay down debt or offer returns to shareholders through dividends or share buybacks, the analysts said.Because the companies can leverage their assets to borrow additional capital, the theoretical firepower of the 18 drugmakers would be enormous at more than $1.7 trillion, the analysts wrote."
https://www.fiercepharma.com/pharma/m-a-large-biotech-pharma-companies-will-have-1-7t-firepower-for-dealmaking-2022